Results 11 to 20 of about 47,298 (270)
Neurologic Clinics, 2018 Ocular myasthenia is a form of myasthenia gravis in which weakness is restricted to the ocular muscles and may produce significant visual disability. Patients present with fluctuating ptosis, diplopia, or a combination of both. Examination may show any type of ocular motility deficit ranging from isolated muscle palsy to complete ophthalmoplegia. Cogan
Mohammed, Al-Haidar +2 more
core +4 more sources
Medicinski pregled, 2011 Introduction. Juvenile myasthenia is a chronic autoimmune neuromuscular disease characterized by varying degrees of fluctuating, painless muscle weakness and rapid fatigue of any muscles under voluntary control. Juvenile myasthenia is a form of myasthenia appearing in adolescent age, representing 10% to 15% of all cases of myasthenia gravis.
Marija Knezevic-Pogancev
openaire +4 more sources
Orphanet Journal of Rare Diseases, 2007 Myasthenia gravis (MG) is a rare, autoimmune neuromuscular junction disorder. Contemporary prevalence rates approach 1/5,000. MG presents with painless, fluctuating, fatigable weakness involving specific muscle groups. Ocular weakness with asymmetric ptosis and binocular diplopia is the most typical initial presentation, while early or isolated ...
Juel, Vern C, Massey, Janice M
openaire +4 more sources
Dental Care in Patients with Myasthenia Gravis
Česká Stomatologie a Praktické Zubní Lékařství, 2010 Myasthenia gravis is an autoimmune disease in the neuromuscular transmission, causing muscular weakness and fatique especially in the facial and pharyngeal muscles.
J. Piťha
doaj +1 more source
Nature Reviews Disease Primers, 2019 ZusammenfassungDie Myasthenia gravis (MG) beruht auf einer durch Autoantikörper (Ak) gegen Acetylcholinrezeptoren (AChR) bzw. andere Strukturproteine der neuromuskulären Endplatte verursachten neuromuskulären Überleitungsstörung mit vorzeitiger Erschöpfbarkeit und teils manifesten Paresen einschließlich der bulbären und okulären Muskulatur. Während die
Wolfgang, Müllges, Guido, Stoll
+9 more sources
Autoimmunity, 2004 Myasthenia gravis is a disorder of neuromuscular transmission, manifest by variable weakness of skeletal muscle. The disorder has a range of therapies that differ with respect to efficacy, timing, and side effects. The physician treating myasthenia gravis must be well versed in understanding the evidence basis for using these agents, as well as the ...
Vincent, A, Rothwell, P
openaire +5 more sources
Identification of genetic risk loci and prioritization of genes and pathways for myasthenia gravis : a genome-wide association study [PDF]
, 2022 Myasthenia gravis is a chronic autoimmune disease characterized by autoantibody-mediated interference of signal transmission across the neuromuscular junction.
Tienari, Pentti J. +5 more
core +1 more source
New England Journal of Medicine, 1978 The basic abnormality in myasthenia gravis (MG) is a reduction in acetylcholine receptors (AChRs) at neuromuscular junctions due to the effects of autoantibodies that are directed against the AChRs in most patients, or against neighboring proteins involved in the clustering of AChRs (MuSK, LRP-4, or agrin).
openaire +3 more sources
Antibodies to acetylcholine receptor in parous women with myasthenia: evidence for immunization by fetal antigen [PDF]
, 2002 The weakness in myasthenia gravis (MG) is mediated by autoantibodies against adult muscle acetylcholine receptors (AChR) at the neuromuscular junction; most of these antibodies also bind to fetal AChR, which is present in the thymus.
Wilcox, Nick +13 more
core +1 more source
Fatigue and Muscle Atrophy in a Mouse Model of Myasthenia Gravis Is Paralleled by Loss of Sarcolemmal nNOS [PDF]
, 2012 Myasthenia Gravis (MG) patients suffer from chronic fatigue of skeletal muscles, even after initiation of proper immunosuppressive medication. Since the localization of neuronal nitric oxide synthase (nNOS) at the muscle membrane is important for ...
Meinen, Sarina +7 more
core +1 more source